Calliditas Therapeutics AB (LTS:0A5R) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Sep. 21, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Calliditas Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Calliditas Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Calliditas Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Calliditas Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Calliditas Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Calliditas Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate falls into.

Calliditas Therapeutics AB (LTS:0A5R) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Calliditas Therapeutics AB Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Calliditas Therapeutics AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (LTS:0A5R) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

CALT:USA CALTX:Sweden CALTXs:UK LC8:Germany

Address

Kungsbron 1, D5, Stockholm, SWE, SE-111 22

Website

https://www.calliditas.se

Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.

Calliditas Therapeutics AB Headlines

No Headlines